home > ebr > winter 2022 > modelling genetic disease: ips cell line development using gene editing


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

Abzena bolsters senior leadership team with two key appointments

San Diego, CA, 14th March 2023 Abzena, the leading end-to-end integrated CDMO for Antibody Drug Conjugates (ADCs) and complex biologic molecules, has strengthened its senior leadership team with the appointment of Joe Principe as Chief Commercial Officer, and Matthew Pinkston as Vice President, Program Management.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement